Inhibrx Biosciences Quarterly Balance Sheet
NASDAQ: INBXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Inhibrx Biosciences financial position
As of Jun 30, 2026, Inhibrx Biosciences reported total assets of $154.2 million, down 27.3% from a year earlier against total liabilities of $207.2 million. Shareholders' equity was negative at -$53.0 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $133.3 million in cash and equivalents against $176.3 million of debt, a net debt position of $42.9 million.
The current ratio (current assets divided by current liabilities) was 5.07, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Inhibrx Biosciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 133.34M | 161.66M | 124.22M | 153.09M | 186.57M | 216.52M | 152.60M | 196.33M | 226.86M | 252.48M | 277.92M | 337.33M |
| Total Current Assets | 142.21M | 171.34M | 132.83M | 161.42M | 193.96M | 223.39M | 160.40M | 207.45M | 242.06M | — | 295.36M | — |
| Property, Plant & Equipment | 2.69M | 3.20M | 3.73M | 4.31M | 4.88M | 5.55M | 6.20M | 6.88M | 7.61M | — | 6.42M | — |
| Total Assets | 154.22M | 183.97M | 146.48M | 177.47M | 212.12M | 242.64M | 180.77M | 222.56M | 258.42M | — | 307.89M | — |
| Accounts Payable | 9.80M | 8.76M | 5.94M | 6.77M | 8.29M | 8.89M | 9.24M | 12.37M | 13.02M | — | 10.95M | — |
| Total Current Liabilities | 28.06M | 26.51M | 33.80M | 35.98M | 38.94M | 43.64M | 40.73M | 44.09M | 39.05M | — | 56.31M | — |
| Long-Term Debt | 176.28M | 174.99M | 100.56M | 99.92M | 99.28M | 98.65M | 0 | 0 | 0 | — | 206.97M | — |
| Total Liabilities | 207.20M | 205.00M | 138.49M | 140.64M | 143.56M | 148.20M | 47.18M | 44.09M | 39.05M | — | 264.39M | — |
| Shareholders' Equity | -52.98M | -21.04M | 7.99M | 36.83M | 68.56M | 94.44M | 133.58M | 178.47M | 219.37M | 11.57M | 43.50M | 129.59M |
| Retained Earnings | -316.28M | -279.63M | -246.19M | -213.35M | -178.10M | -149.44M | -106.13M | -58.27M | -14.40M | — | -613.73M | — |
| Total Debt | 176.28M | 174.99M | 100.56M | 99.92M | 99.28M | 98.65M | 0 | 0 | 0 | — | 206.97M | — |
| Net Cash (Debt) | -42.94M | -13.34M | 23.66M | 53.17M | 87.29M | 117.87M | 152.60M | 196.33M | 226.86M | 252.48M | 70.96M | 337.33M |
| Shares Outstanding | 14.71M | 14.61M | 14.58M | 14.50M | 14.48M | 14.48M | 14.48M | 14.48M | 14.48M | — | 47.37M | — |
This table shows 12 quarterly periods of Inhibrx Biosciences's balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow INBX's reporting calendar. What is a balance sheet?